1. 256 Single-agent zalifrelimab (anti-CTLA-4) shows clinical benefit in rare tumors – case report from phase 2 study (NCT03104699). (9th November 2020) Authors: Perez, Cesar; Wesolowski, Robert; Wilky, Breelyn; Feliu, Waldo Ortuzar; Zhang, Hong; Shapiro, Irina; Wijatyk, Anna; Kaleta, Remigiusz; Trent, Jonathan Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A155 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 256 Single-agent zalifrelimab (anti-CTLA-4) shows clinical benefit in rare tumors – case report from phase 2 study (NCT03104699). (9th November 2020) Authors: Perez, Cesar; Wesolowski, Robert; Wilky, Breelyn; Feliu, Waldo Ortuzar; Zhang, Hong; Shapiro, Irina; Wijatyk, Anna; Kaleta, Remigiusz; Trent, Jonathan Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A279 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 267 Pseudoprogression patterns: Analysis from 2 independent phase-2 studies with immunotherapy for recurrent cervical cancer. (9th November 2020) Authors: O'Malley, David; Feliu, Waldo Ortuzar; Ray-Coquard, Isabelle; O'Neal, Michael; Alexandre, Jerome; Cole, Julie; Ludwig, Robert; Nallewar, Madhavi; Buell, Jennifer; Kaleta, Remigiusz; Wijatyk, Anna; Borisovskaya, Victoria Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A164 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 267 Pseudoprogression patterns: Analysis from 2 independent phase-2 studies with immunotherapy for recurrent cervical cancer. (9th November 2020) Authors: O'Malley, David; Feliu, Waldo Ortuzar; Ray-Coquard, Isabelle; O'Neal, Michael; Alexandre, Jerome; Cole, Julie; Ludwig, Robert; Nallewar, Madhavi; Buell, Jennifer; Kaleta, Remigiusz; Wijatyk, Anna; Borisovskaya, Victoria Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A293 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 398 AGEN1181, an Fc engineered anti-CTLA-4 antibody, demonstrates clinical activity, alone or in combination with balstilimab (anti-PD-1), and broadens the therapeutic potential of CTLA-4 therapy. (9th November 2020) Authors: O'Day, Steven; khoueiry, Anthony El; Ramamurthy, Chethan; Bullock, Andrea; Shapiro, Irina; Han, Haiyong; Namagerdi, Lernik Ohanjanian; Kaleta, Remigiusz; Wijatyk, Anna; Wijatyk, Olivia; Ortuzar, Waldo; Ancukiewicz, Marek; Buell, Jennifer; Chand, Dhan; Gordon, Michael Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A242 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗